Skip to main content

docdok.health increases safety of coronavirus vaccinations

| News

docdok.health increases safety of coronavirus vaccinations

23.02.2021

The Basel-based startup docdok.health has developed an app that aims to increase the safety and efficacy of COVID-19 vaccinations. The company has agreed a partnership with the German umbrella organization of specialized physicians (SpiFa).

As detailed in a press release, the Basel startup docdok.health AG is the new innovation and technology partner of SpiFa (Spitzenverband Fachärzte Deutschland), the German umbrella organization of specialized physicians. SpiFa has recommended to its members – some 160,000 doctors – that they should use an app developed by docdok.health after COVID-19 vaccinations.

The app can be used to collect data which is then anonymously forwarded on to the Paul Ehrlich Institute, otherwise known as the Federal Institute for Vaccines and Biomedicines in Germany. A broad database should also allow processes to be optimized, which will result in improved safety and efficacy for COVID-19 vaccinations.

“We see huge potential for our app in Switzerland”, comments Yves Nordmann, co-founder and Chief Medical Officer (CMO) of docdok.health, in the press release. Founded in 2017, docdok.health AG develops solutions to improve communications between doctor and patient. “The focus is on healthcare provision that prioritizes quality over quantity with the help of digital therapy solutions”, explains co-founder and CEO Ulrich Mühlner, who was also formerly a Senior Manager at Novartis.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.